Getting it right on value frameworks | By: Former Rep. Jim Greenwood (R-Pa.)

Sep 29, 2016

“Value” — especially in the context of healthcare and medicine — is a word that gets used so often these days, and in so many different ways, that it can be difficult to pin down exactly what it means – or should mean.

Read More ›

4 recommendations for ICER | By: Lauren Neves

Sep 26, 2016

For years, PhRMA has supported policies that ensure health care decisions are grounded in the best available evidence. In our policy solutions for delivering innovative treatments to patients released earlier this year, we reiterate our belief that well-designed tools for value assessment can ease the way for a shift to a value-based health care system. The right tools, including value frameworks, can empower health care decision-making and ensure the right treatments reach the right patients at the right time.

Read More ›

California Life Sciences Association Answers ICER’s Call for Improvements to its Value Assessment Framework for Evaluating New Therapies

Sep 19, 2016

CLSA identifies several areas of concern and suggestions for improvement regarding the cost and value of new drugs and medical technologies

Read More ›

IfPA Urges ICER to Improve Value Framework

Sep 16, 2016

Along with other advocacy, education and health care organizations, the Institute for Patient Access wrote to the Institute for Clinical and Economic Review this week offering 12 suggestions on how to improve its value framework. The letter responded to ICER’s request for feedback as it prepares to update its framework for 2017.

Read More ›

Association of Community Cancer Centers Comments on ICER's Value Assessment Framework

Sep 14, 2016

Thank you for the opportunity to comment on the Institute for Clinical and Economic Review’s (ICER’s) Value Assessment Framework. The Association of Community Cancer Centers (ACCC) is a membership organization whose members include hospitals, physicians, nurses, social workers, and oncology team members who care for millions of patients and families fighting cancer. ACCC represents more than 23,000 cancer care professionals from approximately 2,000 hospitals and private practices nationwide, and it is estimated that 65 percent of cancer patients are treated by a member of ACCC.

Read More ›

National Health Council ICER Value Framework Comment Letter | By: Marc Boutin, JD

Sep 13, 2016

The National Health Council (NHC) appreciates the opportunity to provide input on the 2017 update to ICER’s Value Assessment Framework. The NHC is the only organization that brings together all segments of the health community to provide a united voice for the more than 133 million people with chronic diseases and disabilities and their family caregivers. Made up of more than 100 national health-related organizations and businesses, the NHC's core membership includes the nation’s leading patient advocacy organizations, which control its governance and policy-making process.

Read More ›

PIPC Submits Letter to ICER on Value Assessment Process | By: Tony Coelho

Sep 13, 2016

The Partnership to Improve Patient Care (PIPC) and over 40 organizations representing patients, people with disabilities and providers submitted a letter to the Institute for Clinical and Economic Review (ICER) in response to their request for input on their value assessment process.  In the letter, the organizations stated, “Simply put, if we aren’t paying for care that patients’ value, we aren’t really paying for value-based care.”

Read More ›

BIO Submits Comments Re: ICER Value Framework | By: Lauren L. Todd

Sep 13, 2016

BIO submitted comments on the Institute for Clinical and Economic Review (ICER) Value Assessment Framework. Throughout the attached letter, BIO addresses issues it has raised previously with the Framework as well as responds specifically to the four major categories of issues that the Institute identified (in the order in which they were identified). 

Read More ›

Is the Cure Worth the Cost? The debate over the price of specialty drugs. | Presented by: American Enterprise Institute

Sep 13, 2016

American Enterprise Institute presented a panel discussion around the costs of speciality drugs on September 12, 2016 in Washington D.C.

Panelists included:

Gregg Alton, Gilead
Peter B. Bach, Memorial Sloan Kettering Cancer Center
Scott Gottlieb, AEI
Joshua Ofman, Amgen
Steven Pearson, Institute for Clinical and Economic Review
Tomas J. Philipson, University of Chicago; AEI

Read More ›

Patients Rising Public Comments on ICER Value Framework | By: Terry Wilcox

Sep 12, 2016

As stated before, Patients Rising is a non-profit with a very specific mission: We fight for access to vital therapies and services for all patients with life-threatening and chronic diseases. We believe that if a patient needs medicines to survive and live a better quality and more productive life – access to those treatments is warranted and essential. This is part of our desire for a balanced dialogue and national conversation that tells the truth about healthcare.

Read More ›



Mexico has been granted with the honor of hosting the #VIIWFER thanks to the support of #ARIAE the regional associa…

10 hours ago

RT @wfer2018: Did you know #ICER is the biggest association of regulatory authorities with more than 200 members worldwide? #VIIWFER

16 hours ago